Spots Global Cancer Trial Database for Lucentis as an Adjuvant Therapy With TTT-ICG Based in Choroidal Melanoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Lucentis as an Adjuvant Therapy With TTT-ICG Based in Choroidal Melanoma
Official Title: Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma
Study ID: NCT00680225
Conditions
Interventions
Study Description
Brief Summary: To report preliminary results on safety and tolerability of intravitreal injection of Ranibizumab (Lucentis) combined with Transpupillary Thermotherapy (TTT)+ Indocyanine Green (ICG)-based photodynamic therapy (PDT) in the treatment of choroidal melanoma.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: Yes
Locations
New England Retina Associates, Hamden, Connecticut, United States
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
